Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients

Association of Hyperuricemia and Non Alcoholic Fatty Liver Disease and Liver Fibrosis Risk in Adult Obese Patients

1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients.
2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression.

3 - To examine the relationship between serum uric acid levels and liver fibrosis severity*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD.

4- To identify potential mechanisms underlying the association*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.

Study Overview

• Status: Not yet recruiting
• Conditions: Hyperuricemia; Liver Fibrosis; NAFLD (Nonalcoholic Fatty Liver Disease)
• Intervention / Treatment: Diagnostic test: *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .; Radiation: *Imaging Studies:* 1- Ultrasound 2 - FibroScan; Device: Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.

Detailed Description

Hyperuricemia is associated with nonalcoholic fatty liver disease (NAFLD), whereas whether the association differed by hyperuricemia onset age remained unclear. This study sought to investigate the associations of hyperuricemia onset age with the risk of incident NAFLD across adulthood.

Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD). Since both serum uric acid (SUA) and obesity are essential components of metabolic syndrome (MetS), it is uncertain whether the incidence of NAFLD results from serum uric acid, obesity, or other potential factors based on previous studies.

• Study Type: Observational
• Enrollment (Estimated): 111

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adult obese patients

Description

Inclusion Criteria:

1. Age: Adults (typically 18-65 years old)

2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg/m²

3- Hyperuricemia : Elevated serum uric acid levels (typically > 7 mg/dL for men and > 6 mg/dL for women)

Exclusion Criteria:

• excessive alcohol consumption ( > 20 gm /day in men and 10 in g /day in women )

  2- use of steatogenic within the past 6 months

  3- positive test for hepatitis B surface antigen and hepatitis B core antibody

  4- Drug induced liver injury and autoimmune hepatitis

  5 - cirrhosis and other causes of liver disease

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy controls	Diagnostic test: *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .; Lab methods; Radiation: *Imaging Studies:* 1- Ultrasound 2 - FibroScan; Imaging; Device: Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.; Instrument
1- obese +-nafld+- fibrosis; Obese patients with non alcoholic fatty liver disease with fibrosis	Diagnostic test: *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .; Lab methods; Radiation: *Imaging Studies:* 1- Ultrasound 2 - FibroScan; Imaging; Device: Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.; Instrument
obese +- hyperuricemia +- nfld+- fibrosis; Obese patients with hyperuricemia and non alcoholic liver disease and fibrosis	Diagnostic test: *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .; Lab methods; Radiation: *Imaging Studies:* 1- Ultrasound 2 - FibroScan; Imaging; Device: Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.; Instrument

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of NAFLD	The proportion of adult obese patients with NAFLD in the study population	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum uric acid level	The serum uric acid level in adult obese patients	1 year

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: August 27, 2025
• First Submitted That Met QC Criteria: September 4, 2025
• First Posted (Estimated): September 11, 2025

Study Record Updates

• Last Update Posted (Estimated): September 15, 2025
• Last Update Submitted That Met QC Criteria: September 12, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Digestive System Diseases; Liver Diseases; Fibrosis; Fatty Liver; Pathological Conditions, Signs and Symptoms; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Investigative Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Digestive System; Hematologic Tests; Liver Function Tests
• Other Study ID Numbers: UNLF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No